Literature DB >> 6106045

Relation of the neuroendocrine system to the development and growth of experimental mammary tumors.

J Meites.   

Abstract

The regulation of hormonal influences on mammary tumor development and growth resides in the hypothalamus. The two major hormones essential for mammary tumor development in the rat and mouse, and also for mammary tumor growth in the rat, are prolactin and estrogen. Prolactin secretion is directly controlled by the hypothalamus, and estrogen indirectly via the pituitary gonadotropins. Treatments that increase prolactin secretion in the rat and mouse increase the incidence of spontaneous mammary tumors, whereas treatments that decrease prolactin or estrogen secretion decrease the incidence of spontaneous mammary tumors in these species. In carcinogen treated rats, either an increase or decrease in prolactin or ovarian hormones inhibits development of mammary cancers. After the appearance of mammary tumors in rats, spontaneous or carcinogen-induced, a reduction in prolactin results in reduced mammary tumor growth, and an increase in prolactin in enhanced mammary tumor growth. Either a reduction in estrogen or an excess of estrogen inhibits mammary tumor growth in rats. Large doses of estrogen inhibit mammary tumor growth by preventing prolactin from stimulating tumor growth. In mice with well established mammary tumors, prolactin or estrogen have relatively little effect since these tumors are largely autonomous.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6106045     DOI: 10.1007/bf01670031

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  27 in total

Review 1.  Etiology of human breast cancer: a review.

Authors:  B MacMahon; P Cole; J Brown
Journal:  J Natl Cancer Inst       Date:  1973-01       Impact factor: 13.506

2.  Prolactin binding to rat mammary tumor tissue.

Authors:  P A Kelly; C Bradley; R P Shiu; J Meites; H G Friesen
Journal:  Proc Soc Exp Biol Med       Date:  1974-07

3.  Brain catecholamines and breast cancer: a hypothesis.

Authors:  B A Stoll
Journal:  Lancet       Date:  1972-02-19       Impact factor: 79.321

4.  Estrogen inhibition of mammary tumor growth in rats; counteraction by prolactin.

Authors:  J Meites; E Cassell; J Clark
Journal:  Proc Soc Exp Biol Med       Date:  1971-09

5.  Prolactin and human breast cancer.

Authors:  J P Minton
Journal:  Am J Surg       Date:  1974-11       Impact factor: 2.565

6.  Estrogen and prolactin receptor concentrations in rat mammary tumors and response to endocrine ablation.

Authors:  E R DeSombre; G Kledzik; S Marshall; J Meites
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

7.  Effects of high hoses of estrogen on prolactin-binding activity and growth of carcinogen-induced mammary cancers in rats.

Authors:  G S Kledzik; C J Bradley; S Marshall; G A Campbell; J Meites
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701

8.  Reserpine and breast cancer in women in germany.

Authors:  H Kewitz; H J Jesdinsky; P M Schröter; E Lindtner
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

9.  Stimulation of growth of carcinogen-induced mammary cancers in rats by thyrotropin-releasing hormone.

Authors:  H J Chen; C J Bradley; J Meites
Journal:  Cancer Res       Date:  1977-01       Impact factor: 12.701

10.  Prolactin concentrations in patients with breast cancer.

Authors:  S Franks; D N Ralphs; V Seagroatt; H S Jacobs
Journal:  Br Med J       Date:  1974-11-09
View more
  9 in total

1.  Age-associated alterations in sympathetic noradrenergic innervation of primary and secondary lymphoid organs in female Fischer 344 rats.

Authors:  Srinivasan ThyagaRajan; Kelley S Madden; Brian Teruya; Suzanne Y Stevens; David L Felten; Denise L Bellinger
Journal:  J Neuroimmunol       Date:  2010-12-24       Impact factor: 3.478

2.  Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethylbenzanthracene-(DMBA)-induced mammary tumorigenesis.

Authors:  D E Blask; S M Hill; K M Orstead; J S Massa
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

3.  Effect of the preventive-therapeutic administration of melatonin on mammary tumour-bearing animals.

Authors:  M C Saez; C Barriga; J J Garcia; A B Rodríguez; E Ortega
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

4.  The role of the pineal gland in neuroendocrine control mechanisms of neoplastic growth.

Authors:  V Lapin; I Ebels
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

5.  L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.

Authors:  S ThyagaRajan; S K Quadri
Journal:  Endocrine       Date:  1999-06       Impact factor: 3.633

6.  Micromethod for the determination of free and total prolactin receptors: measurement of receptor levels in normal and malignant mammary and prostate tissues.

Authors:  M Ben-David; T Kadar; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

7.  Characterization of prolactin receptors in human breast cancer.

Authors:  J P Peyrat; J Djiane; P A Kelly; B Vandewalle; J Bonneterre; A Demaille
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

Review 8.  Contraceptive steroids and the mammary gland: is there a hazard?--Insights from animal studies.

Authors:  G R Rutteman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 9.  Role of dopamine in malignant tumor growth.

Authors:  S Basu; P S Dasgupta
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.